Junxian Zheng

Junxian Zheng


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
CJCheng Jiang
Cheng Jiang
JQJiancheng Qian
Jiancheng Qian
XJXin Jiang
Xin Jiang
SZShuohan Zhang
Shuohan Zhang
JZJunxian Zheng
Junxian Zheng
HWHongwei Wang
Hongwei Wang
Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of widespread societal attention on April 3, 2023. Till now, the clinical safety of pitolisant remains a heatedly debated topic. This study aimed to offer a comprehensive assessment of the safety profile of pitolisant in real‐world clinical settings. Adverse event reports where pitolisant was the primary suspect drug were extracted from the FDA Adverse Event Reporting System database. The clinical characteristics and concomitant drugs of the pitolisant‐associated adverse events were analyzed. The potential adverse event signals of pitolisant were explored using four disproportionality analysis methods. Furthermore, the difference in pitolisant‐associated adverse event signals was investigated concerning sex, age, weight, and dose. A total of 526 reports and 1695 adverse events with pitolisant as the primary suspected drug were identified. The most significant adverse event signals were generally mild and of short duration. The concomitant drugs of pitolisant were highly intricate, mainly included drugs for treating narcolepsy as well as antidepressants. Seven new significant adverse event signals emerged. The safety profile of pitolisant exhibited no significant differences across age and dose groups, although slight variations were observed in relation to sex and weight. The findings from reports of death and life‐threatening outcomes underscore the importance of enhanced monitoring for cardiac and respiratory adverse reactions when utilizing pitolisant. This study provided a broader understanding of the safety profile of pitolisant.

1 July 2025 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
CJCheng Jiang
Cheng Jiang
JQJiancheng Qian
Jiancheng Qian
YLYingyan Lu
Yingyan Lu
JZJunxian Zheng
Junxian Zheng
Background: Cefotaxime has been widely used in the clinical treatment of infections. However, there is still a lack of systematic researches for the adverse event profiles of cefotaxime through large-scale post-marketing monitoring. Methods: This study investigated the adverse event profiles for cefotaxime in the Food and Drug Administration Adverse Event Reporting System database, delving into clinical characteristics, adverse event signals and variations in these signals across subgroups. Results: Compared with Asia, Europe and America more commonly reported once-daily frequency. New severe hepatobiliary disorders were observed in neonates, children, or underweight elderly patients even when using adjusted doses below 1 g. Significant variations in adverse event signals were identified in relation to continent, dose, onset time, and outcome. Conclusions: The existence of non-recommended frequency in Europe and America warrants clinical attention when using cefotaxime. The identification of new severe hepatobiliary disorders highlights the critical need for personalized dosing strategies and intensified liver function monitoring for neonates, children, and elderly individuals with lower body weights. Furthermore, the differences in adverse event signals across subgroups underscore the necessity of developing targeted monitoring protocols. Further research is required to validate the association. Clinical trial number: Not applicable.